149169-92-6

Basic information

• Product Name: p-ter.-Butylphenyl-3-brompropen
• Synonyms: p-ter.-Butylphenyl-3-brompropen
• CAS NO: 149169-92-6
• Molecular Weight: 253.182
• Mol File: 149169-92-6.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: p-ter.-Butylphenyl-3-brompropen(CAS DataBase Reference)
• NIST Chemistry Reference: p-ter.-Butylphenyl-3-brompropen(149169-92-6)
• EPA Substance Registry System: p-ter.-Butylphenyl-3-brompropen(149169-92-6)

Safety Data

• Hazardous Substances Data: 149169-92-6(Hazardous Substances Data)

Upstream product

• 3972-65-4 1-bromo-4-tert-butylbenzene 
• 27798-45-4 1-allyl-4-(tert-butyl)benzene 
• 36215-20-0 methyl (E)-3-(4'-t-butylphenyl)-2-propenoate 
• 86604-07-1 4-tert-butylcinnamaldehyde 
• 35779-04-5 1-tert-butyl-4-iodobenzene 
• 117721-77-4 (E)-3-(4-(tert-butyl)phenyl)prop-2-en-1-ol 
• 20850-03-7 4-tert-butylcinnamyl alcohol 
• 84434-23-1 3-(4-(tert-butyl)phenyl)acrylaldehyde 
• 158010-17-4 ethyl (E)-3-[4-(tert-butylphenyl)]-2-propenoate 
• 939-97-9 4-tert-Butylbenzaldehyde 

Downstream Products

• 149169-91-5 (R)-4-methyl-3-<1-(p-t-butylphenyl)propyl>salicylaldehyde 
• 149169-95-9 (R)-4-methyl-3-<1-(p-t-butylphenyl)propyl>salicylic acid 
• 149169-94-8 (RS)-ethyl 4-methyl-3-<1-(p-t-butylphenyl)propyl>salicylate 
• 1300698-79-6 (E)-5-(4-(tert-butyl)phenyl)pent-4-enoic acid 
• 1464149-44-7 (E)-(3-(4-(tert-butyl)phenyl)allyl)(trifluoromethyl)sulfane 
• 1375536-67-6 (E)-2-(4-(4-(tert-butyl)phenyl)but-3-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 149169-93-7 ethyl 4-methyl-O-(p-t-butylcinnamyl)salicylate 

Relevant articles and documents

Palladium-Catalyzed Allyl-Allyl Reductive Coupling of Allylamines or Allylic Alcohols with H2as Sole Reductant

Catalytic carbon-carbon bond formation building on reductive coupling is a powerful method for the preparation of organic compounds. The identification of environmentally benign reductants is key for establishing an efficient reductive coupling reaction. Herein an efficient strategy enabling H2 as the sole reductant for the palladium-catalyzed allyl-allyl reductive coupling reaction is described. A wide range of allylamines and allylic alcohols as well as allylic ethers proceed smoothly to deliver the C-C coupling products under 1 atm of H2. Kinetic studies suggested that the dinuclear palladium species was involved in the catalytic cycle.

Novel Staphyloxanthin Inhibitors with Improved Potency against Multidrug Resistant Staphylococcus aureus

Diapophytoene desaturase (CrtN) is a potential novel target for intervening in the biosynthesis of the virulence factor staphyloxanthin. In this study, 38 1,4-benzodioxan-derived CrtN inhibitors were designed and synthesized to overwhelm the defects of leading compound 4a. Derivative 47 displayed superior pigment inhibitory activity, better hERG inhibitory properties and water solubility, and significantly sensitized MRSA strains to immune clearance in vitro. Notably, 47 displayed excellent efficacy against pigmented S. aureus Newman, Mu50 (vancomycin-intermediate MRSA, VISA), and NRS271 (linezolid-resistant MRSA, LRSA) comparable to that of linezolid and vancomycin in vivo.

Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity

CrtN has been identified as an attractive and druggable target for treating pigmented Staphylococcus aureus infections. More than 100 new compounds were synthesized, which target the overwhelming the defects of the CrtN inhibitor 1. Analogues 23a and 23b demonstrated a significant activity against pigmented S. aureus Newman and 13 MRSA strains (IC50 = 0.02-10.5 nM), along with lower hERG inhibition (IC50 > 30 μM, ～10-fold decrease in comparison with 1). Furthermore, 23a and 23b were confirmed to reduce the staphylococcal load in the kidney and heart in a mouse model with normal treatment deeper than pretreatment ones, comparable even with vancomycin and linezolid. Remarkably, 23a could strongly block the pigment biosynthesis of these nine multidrug-resistant MRSA strains, including excellent activity against LRSA strains and VISA strains in vivo, and all of which demonstrated that 23a has a huge potential against intractable MRSA, VISA, and LRSA issues as a therapeutic drug.